PROK — PROKIDNEY CORP.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1850270 ·
Last close
$1.66
Market Cap
$346.82M
52W High
$3.48
52W Low
$1.30
ADV30
1,506,909
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 150,000 | — | -48,373,000 | -28,422,000 | 249,016,000 | 74,868,000 | 26,178,000 |
| Mar 2026 | 226,000 | — | -44,933,000 | -20,037,000 | 292,784,000 | 101,895,000 | 29,680,000 |
| Dec 2025 | 225,000 | — | -45,371,000 | -19,231,000 | 335,574,000 | 108,537,000 | 34,781,000 |
| Sep 2025 | 217,000 | — | -38,539,000 | -16,469,000 | 351,608,000 | 95,323,000 | 33,270,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,209,000
Investing CF
$110,503,000
Financing CF
$25,796,000
CapEx
$-17,846,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,289,872,000
Inventory
—
Receivables
$1,032,000
ST Investments
$123,049,000
EBIT TTM
$-156,439,000
Pretax Income TTM
$-156,458,000
Interest Exp TTM
$19,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$818,000
EBITDA
$-170,370,000
Free Cash Flow
$-83,844,872
Enterprise Value
$1,304,397,440
Total Cash
$181,564,000
Total Debt
$3,523,000
Shares Out
208,926,941
Trailing EPS
$-0.55
Book Value
$-4.29
ROE
-59.0%
ROA
-35.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 893,000 | -165,007,000 | -68,986,000 | 335,574,000 | 34,781,000 | -1,011,197,000 | -120,117,000 |
| Dec 2024 | 76,000 | -183,676,000 | -61,186,000 | 441,073,000 | 39,436,000 | -994,954,000 | -126,351,000 |
| Dec 2023 | 0 | -151,522,000 | -35,468,000 | 420,552,000 | 29,216,000 | -1,103,396,000 | -90,069,000 |
| Dec 2022 | 0 | -153,007,000 | -108,032,000 | 517,996,000 | 13,057,000 | -1,096,616,000 | -77,089,000 |
TTM Snapshot
Revenues TTM
$889,000
NetIncome TTM
$-72,289,000
OpCashFlow TTM
—
Assets (Latest)
$292,784,000
Forward EPS
$-0.59
Max Pain — expiry 2027-01-15
max pain strike: $2.00 · spot: $1.74 · call oi: 1,771 · put oi: 290
Expected Move to 2027-01-15:
±$0.90
(51.87%) —
implied range
$0.84 –
$2.64
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | $350.62M | $2.85 | — |
| AGEN | AGENUS INC | $339.45M | $7.54 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $332.45M | $6.80 | — |
| OCGN | Ocugen, Inc. | $331.45M | $0.98 | — |
| CABA | Cabaletta Bio, Inc. | $330.61M | $1.95 | — |
News headlines (Yahoo Finance, 1h cache)
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
2026-09-11 05:28 · Yahoo
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
2026-06-17 15:16 · Yahoo
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 16:55 · Yahoo
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 15:45 · Yahoo
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
2026-05-01 09:23 · Yahoo
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
2026-10-02 13:00 · Yahoo
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
2026-08-10 21:55 · Yahoo
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
2026-08-10 20:05 · Yahoo
Identiv And Two Other Penny Stocks To Watch Closely
2026-06-05 18:15 · Yahoo
ProKidney Appoints Kenneth Locke as Chief Technical Officer
2026-06-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.